Advertisement

Topics

Companies Related to "Proposes Subscription Model Prod Antibiotic Development" [Most Relevant Company Matches] RSS

01:17 EDT 24th March 2019 | BioPortfolio

Here are the most relevant search results for "Proposes Subscription Model Prod Antibiotic Development" found in our extensive corporate database of over 50,000 company records.

Showing "Proposes Subscription Model Prod Antibiotic Development" Companies 1–25 of 6,400+

Relevant

Microbiotix, Inc.

Microbiotix, Inc. is a privately held, product-focused biopharmaceutical company engaged in the research and development of novel small molecule, anti-infective drugs that address commercially significant medical markets. The company currently has four novel compound series in research and development. Microbiotix currently has in development MBX 500, the first antibiotic that targets the DNA po...


Epikure SA - Drug Delivery Systems

Epikure SA provides consulence and manages development projects in the pharmaceutical field, and proposes to the customers innovative technologies and products.

Pharmaceutica Limited

Pharmaceutica Limited is a privately owned pharmaceutical company founded in March 2003, to discover and develop a new generation of anti-infective drug technologies that combat the increasing problem caused by the rapid evolution of resistance by pathogenic organisms. The company is targeting both human and veterinary applications for its technologies.The initial focus is to find a solution to th...


RRD International

Founded in 2002, RRD is a strategy-driven product development company. The Company's development model enables rapid proof-of-concept for biotech and pharmaceutical clients to accelerate value inflection points; reduce costs; and mitigate development as well as execution risk. RRD offers two distinct types of client engagements: TacDev® and DevCo®. The TacDev® model adds development bandwid...

PolyMedix, Inc.

PolyMedix is a publicly traded biotechnology company focused on the development of novel drugs and biomaterials for the treatment of serious acute cardiovascular disorders and infectious diseases. PolyMedix uses a rational drug design approach to create non-peptide small molecule drug candidates and polymers that mimic the activity of proteins. PMX-60056, ...

Ipsat Therapies Oy

Ipsat Therapies Ltd is a Finnish biotechnology company developing its proprietary IPSAT™ (“Intestinal Protection System in Antibiotic Treatment”) family of products for the prevention of hospital infections and antibiotic resistance

AdvanDx, Inc.

AdvanDx is a leading provider of rapid and accurate molecular diagnostic tests for identification of pathogens that cause critical infections in hospitalized patients. Our mission is to improve antibiotic decision-making and patient outcomes while limiting unnecessary and inappropriate antibiotic use and reducing healthcare costs.

Australian Pharmaceutical Publishing Company

The Australian Journal of Pharmacy is now accessible as an Online version at its own website www.ajp.com.auTo subscribe to the AJP via our online form system please click on the folowing link to the Subscription webpage.To subscribe to the AJP via Phone or Fax please click on the following link to the Subscription (pdf).

PX’Therapeutics SA

PX’Therapeutics, located in Grenoble and Lyon (France) and with a sales office in Cambridge (MA, USA), offers early stage research and cGMP manufacturing contracts focusing on the development of protein therapeutics, monoclonal antibodies and recombinant vaccines. PX’Therapeutics proposes custom programs targeting the generation of murine antibod...

New England Journal of Medicine

The New England Journal of Medicine is published weekly, and the term of a regular subscription is for one year (52 weeks). Subscribers can elect to receive either a Print and Online Subscription or an Online-only Subscription. Regular sections of the New England Journal of Medicine include:• Research: The core of the Journal, our Research articles present the most important findings in medi...

NEOSPORIN(R)

NEOSPORIN® Original First Aid Antibiotic Ointment, from the #1 Doctor-recommended brand, provides long-lasting infection protection and kills more types of infectious bacteria in laboratory tests than even the leading topical prescription antibiotic. Plus, NEOSPORIN® Original First Aid Antibiotic Ointment and a bandage help heal minor wounds four days faster than a bandage alone and may help min...

SoluMed.com

SoluMed.com offers two alternatives for selling medical equipment via our eMarketplace, Medical EquipNet™. The Company offers a Subscription model whereby users pay a fixed upfront monthly fee to advertise equipment sales. Alternatively, users may choose the Transaction model whereby listings are free and sellers pay a fee at the time of the equipment sales transaction out of the sales proceeds....

OMNICON Company

Manufacturers of the OMNICON Zone Reader for Antibiotic Potency Testing - Zones of Inhibition - Fisher Lilly Antibiotic Zone Reader - Peni Cylinder - Peni Cylinder Dispenser - Large Plate - NUNC Bio-Assay Dish

Monthly Gift.

Founded, owned and operated by women in New York City, Monthly Gift. is a feminine care subscription-based service powered by technology and empowering women to take control of their health. Catering to users’ personal cycles, the Monthly Gift. App monitors ovulation and menstrual cycle patterns, while the subscription delivers a discreet, Little Black ...

Arsanis Inc

Arsanis is committed to the development of monoclonal antibody therapeutics against severe infectious diseases that cannot be controlled with currently available medical treatments. The company’s major focus is on life threatening infections that are caused by antibiotic resistant pathogens, occur in immune compromised patients or are associated with ...

VenatoRx Pharmaceuticals, Inc.

VenatoRx Pharmaceuticals is a private pharmaceutical company dedicated to the discovery and development of novel agents to address the threat of antibiotic bacteria resistance. Its lead clinical program combines VNRX-5133, a novel β-lactamase inhibitor, with an approved and marketed β-lactam antibiotic. This press release contains “forward-looking ...

Arsanis, Inc

Arsanis is committed to the development of monoclonal antibody therapeutics against severe infectious diseases that cannot be controlled with currently available medical treatments. The Company’s major focus is on life threatening infections that: are caused by antibiotic resistant pathogens; occur in immune compromised patients; or are associated wit...

Arsanis Biosciences GmbH

Arsanis is committed to the development of monoclonal antibody therapeutics against severe infectious diseases that cannot be controlled with currently available medical treatments. The Company’s major focus is on life threatening infections that are caused by antibiotic resistant pathogens, occur in immune compromised patients or are associated with ...

Arsanis, Inc.

Arsanis is committed to the development of monoclonal antibody therapeutics against severe infectious diseases that cannot be controlled with currently available medical treatments. The Company’s major focus is on life threatening infections that: are caused by antibiotic resistant pathogens; occur in immune compromised patients; or are associated wit...

Healthation, Inc.

Healthation is a comprehensive, rules-based, and user-configurable core administrative system that offers a single, Web-based platform for all healthcare lines of business, including medical, dental, vision and pharmacy. Today, Healthation supports 26 customers representing nearly 24 million members. The company's offerings are available via a SaaS subscri...

Mpex Pharmaceuticals

Mpex Pharmaceuticals is focused on the discovery and development of new anti-bacterial drugs that meet the growing clinical need created by multi-drug resistant bacterial pathogens. It is well documented that antibiotic resistance is a growing, serious problem in both the hospital and community setting. Mpex's approach is to improve the activity of existing antibiotics by utilizing methods and pot...

Panlabs Incorporated

Drug discovery servicesAssay development and optimization Pharmacological profiling Process improvement servicesFermentation yield improvement (classical and molecular) Fermentation process development Pathway engineering Gene expression Bio-transformation Antibiotic technologies

Phage Biotech Ltd.

Phage-Biotech Ltd. was incorporated in March 2000, as a new player in the emerging field of Phage Therapy. The Company’s mission is to develop proprietary Phage-based anti-infective therapeutics to combat the increasing number of antibiotic-resistant infections worldwide. The Company has two short-term strategic objectives:To identify and formulate proprietary topical Phage preparations from dis...

Sense Technology Inc.

In 1991, the Precision Adjustor was redesigned to simplify the manufacture and lower the price. The new instrument was called the Model 4. This model was further refined and renamed the Model 5 in 1992. The Model 5 included the option of single or multiple adjustments.In 1992, it was observed by doctors using the Precision Adjuster that the sound generated by the multiple toggle adjustment changed...

RegeneRx Biopharmaceuticals

RegeneRx is a publicly-traded biopharmaceutical company focused on the discovery and development of novel molecules to accelerate tissue and organ repair. Our stock is traded on the American Stock Exchange (AMEX) under the symbol RGN. We are headquartered in Bethesda, Maryland.RegeneRx utilizes an outsourcing business model in order to effectively control costs while focusing on clinical developme...


More From BioPortfolio on "Proposes Subscription Model Prod Antibiotic Development"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks